Compare Amphastar Pharmaceuticals Inc (AMPH) vs PubMatic Inc (PUBM) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

PubMatic (PUBM) trades at $13.55, showing minimal daily movement (-0.07%) with a bullish technical outlook supported by moving averages. The company reported mixed Q1 2026 results, beating EPS expectations but posting a net loss, while maintaining strong operational cash flow of $81M in 2025. Recent partnerships with Level Agency and Gracenote highlight growth in AI-powered advertising and CTV markets.

Investment outlook balances analyst optimism (50% buy ratings, $17 consensus target) against fundamental challenges including negative profit margins and elevated P/E ratio. Key risks include competitive pressure in ad tech and execution on AI initiatives, while institutional sentiment remains divided between growth potential and current profitability concerns.